Atlante Ventures is a leading Italian VC fund, operated by IMI Fondi Chiusi SGR, part of Intesa Sanpaolo Group.   Totalling, together with its companion funds Atlante Ventures Mezzogiorno (AVM) and Atlante Seed, 60 mio euros in funds under management, Atlante Ventures only supports truly innovative startups, in Italy and abroad.    Since inception from 2007, Atlante Ventures, AVM and Atlante Seeds have invested in more than 20 seed and early stage companies across all the innovation spectrum, among which Silicon Biosystems, the leading single-cell genomics company, Icoolhunt, the online trend forecasting startup, Admantx, the semantic-based advertising optimization platform    Through its dedicated team of 8 professionales, Atlante Ventures sifts through hundreds of startup companies per year, using the following as key investment criteria: existence of a clearly innovative product or method, strong IP and Know how where applicable, an entrepreneurial team possessing dynamism, common sense, selling skills and in general, the will to make their mark

Atlante Ventures

Omnes VC is the Venture Capital arm of Omnes Capital, a leading private equity firm dedicated to energy transition and innovation with €4.8 billion in assets under management and a 20 year + experience in: venture capital, buyout & growth capital, private debt, renewable energy, co-investment, secondary funds of funds. Omnes Capital is fully independent. With 65 business sales including 14 IPOs carried out in 16 years, Omnes VC is one of the key players in France in financing innovative SMEs with expertise in both Technology and Healthcare sectors. Omnes VC has supported 120 companies and has invested more than €500M in businesses such as Scality, Novaled, BioVex, arGEN-X, Pixium, Blablacar.

Omnes Capital

Innogest is a venture capital firm founded in 2006 with offices in Turin, Milan, Geneva and San Francisco. It manages investment funds for a total value of about €200 million and it invests in  startups mainly in the healthcare and digital sectors mainly in early stage phase. Innogest partners with main local and international research centers and technology transfer offices. In the healthcare field, Innogest invests with a focus on medical devices, diagnostics and digital health and with particular attention to therapeutic areas such as cardiovascular, neurology, and oncology. In the digital field, Innogest invests with a focus on foodtech, fintech, fashion-tech and lifestyle verticals

Innogest Capital

Indaco Venture Partners SGR is the Italian venture capital asset management company, with a strong specialization in companies that innovate in electronics and robotics, medtech, digital, and new materials. The company focused on growth-stage companies whose competitive advantage stems from cutting-edge proprietary technologies and innovations. In terms of teams and technologies, the focus is on Italian enterprises, although investments are made throughout Europe, the USA, Canada, and Israel. Indaco Venture Partners was founded in 2018 and is headquartered in Milan, Lombardia, Italy.

Indaco Venture Partners

Newronika

Newronika restores brain and body functions with innovative technologies. We translate our deep knowledge on biosignal decoding into clinical practice, with the aim of improving treatments, health, and wellness. With our revolutionary brain devices, the patient receives the right stimulation at the right moment, thus becoming able to perform normal daily activities and improve quality of life.  Newronika is the spin-off company of two leading research institutions in Italy, the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan. ​  Newronika comprises a multidisciplinary team formed from Neuroscience research groups and involves scientists with expertise in neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnologies.

Newronika S.P.A. is a pioneering Milan-based company specializing in adaptive deep brain stimulation and brain device interface technology. Their flagship product, the AlphaDBS system, is designed to enhance the lives of Parkinson's disease patients by automatically adjusting therapy throughout the day based on individual patient needs. This adaptive deep brain stimulation system offers a significant advancement over conventional deep brain stimulation methods, providing patients and clinicians with enhanced options for managing deep brain stimulation therapy.

Newronika Sercures Initial €2 Million in Blended Finance from EIC Accelerator for Groundbreaking Parkinson's Disease Research

Transforming neurological care with innovation

Neurostimulation Tech

Newronika Raises €8.4M in Funding

Newronika S.P.A. is a pioneering Milan-based company specializing in adaptive deep brain stimulation and brain device interface technology. Their flagship product, the AlphaDBS system, is designed to enhance the lives of Parkinson's disease patients by automatically adjusting therapy throughout the day based on individual patient needs. This adaptive deep brain stimulation system offers a significant advancement over conventional deep brain stimulation methods, providing patients and clinicians with enhanced options for managing deep brain stimulation therapy.
Newronika was founded as a spin-off company from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milan and the University of Milan, based on groundbreaking research by Professor Dr. Alberto Priori and his team. The company's technology is backed by prominent venture capital funds with extensive experience in the healthcare sector, including Innogest SGR, Indaco Venture Partners, Omnes Capital, F3F, Wille Finance, and TNBT Capital.

Aleva Neurotherapeutics is a medical device company specializing in deep brain stimulation (DBS) systems for treating neurological disorders such as Parkinson's disease and essential tremor. Based in Lausanne, Switzerland, the company was founded as a spin-off from the Swiss Federal Institute of Technology. Aleva pioneered the development of directional DBS leads with its flagship product, the directSTIM DBS system. This technology aims to deliver more precise electrical stimulation to targeted areas of the brain, potentially improving therapeutic benefits and reducing side effects compared to traditional omnidirectional DBS leads.
The directSTIM system features a novel 12-electrode lead design based on microelectromechanical systems (MEMS) technology. This allows for smoother electrode surfaces and customized shapes optimized for implantation in the brain. The system also incorporates 24 independent current sources, enabling greater flexibility in programming and personalizing stimulation patterns to each patient's unique needs. In May 2024, Aleva received CE marking for the directSTIM system, allowing its commercial launch in Europe.
Aleva's expertise in DBS technology is reflected in its robust intellectual property portfolio, comprising 13 patent families and 90 granted patents related to DBS for neurological and psychiatric disorders. The company aims to transform DBS therapy by combining advanced technologies with shared clinical data to improve surgical experiences and patient outcomes.

Aleva Neurotherapeutics

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The company has developed Deep Transcranial Magnetic Stimulation (Deep TMS), a proprietary technology that uses magnetic pulses through a patented H-coil helmet to stimulate deeper and broader brain regions associated with various conditions.
Deep TMS received FDA clearance for treating major depressive disorder (MDD) in 2013, making BrainsWay the first and only TMS company with clinical evidence demonstrating efficacy for this indication. In 2018, the technology obtained FDA clearance for treating obsessive-compulsive disorder (OCD), and in 2021, it was cleared as an aid for short-term smoking cessation.
The Deep TMS treatment is administered through a series of daily sessions over four to six weeks, with each session lasting around 20 minutes. It has been investigated in over 30 randomized clinical trials worldwide, demonstrating its safety and effectiveness. As of April 2021, BrainsWay announced that 100,000 patients have been treated globally with Deep TMS.
In addition to the FDA-cleared indications, BrainsWay is conducting ongoing or planned clinical trials exploring Deep TMS for various psychiatric, neurological, and addiction disorders. The company's commitment to clinical research and building upon its substantial body of evidence positions it as a leader in advancing neuroscience through non-invasive solutions.

Brainsway

Cala Health is a bioelectronic medicine company that has developed the Cala kIQ system, a wearable neuromodulation device that delivers transcutaneous afferent patterned stimulation (TAPS) therapy for the relief of hand tremors in adults with essential tremor and Parkinson's disease. The Cala kIQ system comprises a stimulator, a band with integrated electrodes, and a base station. It utilizes a calibrated TAPS output pattern adjusted to match the patient's unique tremor frequency, providing personalized stimulation to the median and radial nerves of the wrist.
The Cala kIQ system received 510k clearance from the US Food and Drug Administration (FDA) in November 2022 and was launched for human use in June 2023. The device offers treatment sessions of 40 minutes, with a wristband life of 90 days and a shelf life of three months. Patients can review their therapy session results through the MyCala.com patient portal and share them with healthcare providers.
Cala Health has reported positive clinical data demonstrating the effectiveness of TAPS therapy in reducing tremors and improving activities of daily living for essential tremor patients. The company has secured reimbursement and coding from various commercial and government payors, including Medicare, to improve patient access to the therapy.

Cala Health

Cardionomic is a medical device company based in Minneapolis that has developed the Cardiac Pulmonary Nerve Stimulation (CPNS) System, an investigational device designed to treat patients suffering from acute decompensated heart failure (ADHF). The CPNS System consists of a stimulation console and an endovascular catheter that delivers targeted stimulation to the cardiac plexus located in the right pulmonary artery.
The company's approach is founded on the principle that stimulating the autonomic nerves improves a patient's clinical condition by triggering a rebalancing of the autonomic system, shifting it from an imbalanced state into a cycle that enhances the patient's condition even after the therapy is completed. The CPNS System has demonstrated the ability to increase cardiac contractility without significantly affecting heart rate in heart failure patients with reduced ejection fraction.
In January 2024, Cardionomic announced the completion of enrollment in the STIM-ADHF and STOP-ADHF pilot studies, which evaluated the safety and performance of the CPNS System in treating ADHF patients. A total of 35 patients were treated across seven countries. Preliminary results suggest that the CPNS therapy may address the unmet need for more effective treatment options for hospitalized heart failure patients. The pooled data from these studies is planned for publication in early 2024.
The CPNS System leverages engineered electrode surfaces from Pulse Technologies, Inc. to deliver durable electrochemical performance for the neural and cardiac interfacing applications.

Cardionomic

Charco Neurotech was founded in 2019 by Lucy Jung, an industrial designer who was inspired to develop assistive devices for Parkinson's after her own experience as a patient. The CUE1 is a small plastic disc with an electric motor that vibrates at a high frequency in a specialized pattern. This pattern, proven through research, can disrupt the overactive brainwaves that cause Parkinson's symptoms, allowing for improved movement.
The CUE1 attaches to the user's sternum using medical adhesive and is relatively inexpensive compared to other treatments like deep brain stimulation implants. Over 2,000 people in the UK are currently using the CUE1, with a waiting list of almost 20,000 across 120 countries as of March 2024. Charco has raised over USD 10 million in funding and grants, employing around 38 people across the UK, South Korea, and the US.
The device is accompanied by a smartphone app that enables users to personalize the stimulation settings and track their symptoms. Charco aims to obtain regulatory approvals for the CUE1 to be prescribed through healthcare systems like the NHS. In April 2023, Addenbrooke's Hospital in Cambridge became the first hospital to trial the device on inpatients with Parkinson's.
Key customers and partnerships
As of August 2023, over 1,700 people are benefiting from the CUE1 in the UK, and there is a waiting list of over 17,000 people worldwide. Charco has partnered with Dr. Alistair Mackett, a consultant geriatrician at Cambridge University Hospitals, to conduct trials and research on the device's effectiveness.

Charco Neurotech

Companies that offer solutions for pain management, neuropathies, and related disorders and migraines.

Companies that provide solutions for Parkinson's disease, epilepsy, and speech and movement disorders.

Companies that offer treatments for depression, Alzheimer's, and other mental health-related disorders.

Companies that offer solutions for heart-related medical issues such as acute decompensated heart failure and high blood pressure.

Companies that offer solutions for urinary or fecal incontinence, autoimmune diseases and other functional impairments

Companies that offer solutions for hearing or vision impairment, sleep-related conditions, and other disorders, including obesity treatments.

Newronika

Sources

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless